Andrology-Open Access
Open Access
ISSN: 2167-0250
+44 1300 500008
ISSN: 2167-0250
+44 1300 500008
Mochizuki T
Japan
Research Article
Cisplatin, Methotrexate and Bleomycin for Advanced Recurrent or Metastatic Penile Squamous Cell Carcinoma
Author(s): Yasushi Yumura, Kasuga J, Kawahara T, Miyoshi Y, Hattori Y, Teranishi J, Takamoto D, Mochizuki T and Uemura HYasushi Yumura, Kasuga J, Kawahara T, Miyoshi Y, Hattori Y, Teranishi J, Takamoto D, Mochizuki T and Uemura H
Objective: This study aimed to evaluate the efficacy and toxicity of cisplatin, methotrexate, and bleomycin (CMB) chemotherapy in patients with advanced, recurrent, or metastatic penile squamous cell carcinoma (PSCC).
Methods: The CMB regimen was administered to 12 patients with advanced (n=7), recurrent (n=4), or metastatic (n=1) PSCC. Patients received a total of 21 cycles of CMB between 2002 and 2009, and were retrospectively reviewed for treatment efficacy and toxicity of the drugs. The mean patient age was 61 (61.0 ± 8.7) years. Patients received 20.0 mg/m2 of cisplatin intravenously on days 2-6; 200.0 mg/m2 of methotrexate intravenously on days 1, 15 and 22; and 10.0 mg/m2 of bleomycin as a bolus on days 2-6. The CMB regimen consisted of 21-28 days of treatment per cycle. Survival after CMB therapy and frequency and magnitude of ad.. View More»
DOI:
10.4172/2167-0250.1000194